newsfilter
← Latest News
GlobeNewswire·

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reduction compared to baseline in D-dimer levels of 16.8% versus 11.2% for standard of care heparin which was not statistically signif